Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Bausch Health received FDA approval for its topical lotion DUOBRII to treat patients with plaque psoriasis.

Bausch Health Looks At A Revived Way Of Business After Overcoming Hardship

Bausch Health shares rallied after a strong quarter but have room to move higher.

Bausch Health: Headed Higher

Investors need to pay close attention to Bausch Health (BHC) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in Bausch Health (BHC) Stock

Aquantia

Athenex

Marvell Technology

Despite pressure on the broader market, these stocks bucked the downtrend.

Why Bausch Health Companies, Aquantia, and Athenex Jumped Today

Bausch Health Companies Inc. (BHC) CEO Joe Papa on Q1 2019 Results - Earnings Call Transcript

Rising sales in its eye-care segment propelled the drugmaker to its best quarter since 2015.

Bausch Health Companies Posts Strongest Organic Growth in 3 Years

Bausch earnings of $1.03 per share, adjusted, topped estimates Monday, but revenue came in light.

Drug Giant Reports Mixed First Quarter, But Raises Sales Outlook

Bausch (BHC) delivered earnings and revenue surprises of 15.73% and -1.19%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Bausch Health (BHC) Q1 Earnings Top Estimates

Shares of Bausch Health Companies Inc.  , formerly Valeant Pharmaceuticals International Inc.

Shares of Bausch Health gain 2.4% after company raises full-year guidance

It also narrowed its quarterly loss to $52 million from a loss of $2.58 billion a year earlier.

Bausch Health shares jump after the company, formerly Valeant Pharmaceuticals, raises outlook

Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q1 results on May 6.

What's in the Cards for Bausch Health (BHC) Q1 Earnings?

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bausch Health (BHC) Reports Next Week: What Awaits?

Bausch Health Companies Inc (NYSE: BHC) shares were on the rise Thursday after the company announced federal regulators have approved its new psoriasis lotion.

Bausch Health Trades Higher On FDA Approval Of Psoriasis Treatment

Shares of Bausch Health Companies Inc.  shot up 3.6% in afternoon trade Thursday, after the company said its new drug application (NDA) for Duobrii for the treatment of plaque psoriasis in adults was approved by the Food and Drug Administration.

Bausch Health's stock shoots up after NDA for psoriasis treatment gets FDA OK

Bausch Health, formerly known as Valeant Pharmaceuticals, said Thursday that it and its dermatology business, Ortho Dermatologics received approval from the Food and Drug Administration for its DUOBRII lotion to treat plaque psoriasis.

Shares of Bausch Health, formerly Valeant, rise 3% on FDA approval of psoriasis treatment

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Bausch Health: a Great Value Stock?

Value stocks are in short supply in this overheated market. But there are still a few hidden gems to be found.

A slow-motion turnaround: Bausch Health Companies

Bausch (BHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Bausch Rating Upgrade to Buy

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Bausch (BHC) Up 8.3% Since Last Earnings Report?

Bausch Health Companies Inc’s (NYSE: BHC) growth drivers will become “more tangible” in 2019, and shares could appreciate as the company continues to demonstrate good execution, according to Mizuho Securities.

Bullish Mizuho Says Bausch Health's Long-Term Guidance 'Within Reach'

Unbiased review of the pharmaceutical company BHC, as the once Valeant Pharmaceuticals' future hangs in the balance, as they reinvigorate the company into the newly branded Bausch Healthcare, Inc.

News for Bausch Health Companies Inc Stock (BHC)